Sofosbuvir/Velpatasvir Is Effective and Safe in Patients with Concomitant Proton PUMP Inhibitor Use in Clinical Studies
Recommended Citation
Cooper C, Agarwal K, Calleja JL, Dufour JF, Flamm SL, Gordon S, Stamm L, Ni L, Brainard D, Cumaraswamy AA, Kowdley K, Esteban R, Pineda JA, Castells L, Buti M, and Lens S. Sofosbuvir/Velpatasvir Is Effective and Safe in Patients with Concomitant Proton PUMP Inhibitor Use in Clinical Studies. Can Liver J 2019; 2(2):76.
Document Type
Conference Proceeding
Publication Date
8-2019
Publication Title
Can Liver J
Abstract
BACKGROUND: Prior to the availability of Phase 1 drug interaction data, concomitant proton pump inhibitor (PPI) use was prohibited in clinical trials of Sofosbuvir/Velpatasvir (SOF/VEL). Later, clinical studies allowed use of up to 20 mg omeprazole or equivalent dosing. PURPOSE: This analysis evaluated the efficacy and safety of patients with and without compensated cirrhosis who received SOF/VEL for 12 weeks and reported concomitant use of a PPI. METHODS: This was a retrospective analysis of efficacy and safety data from 12 Phase 2 and Phase 3 clinical studies where patients of all genotypes with and without compensated cirrhosis received 12 weeks of SOF/VEL and reported concomitant use of a PPI. Efficacy was assessed by sustained virologic response 12 weeks after treatment (SVR12) and relapse rates and safety was assessed by treatment- emergent adverse events (AEs). RESULT(S): 87 patients reported concomitant use of a PPI. The mean age (range) was 57 years (26- 78), 79% were male and 75% white; 56% of patients were infected with HCV genotype 3 and 29% with genotype 1; 37% of patients had compensated cirrhosis and 39% were treatment experienced. The most common PPI was omeprazole (68% of patients). SVR12 was 97% (84 of 87 patients). Of the 3 patients who did not achieve SVR12, 2 patients relapsed (relapse rate 2%) and one patient with history of diabetes discontinued SOF/VEL after 7 days of dosing due to hyperglycemia. No other patient had an AE leading to discontinuation or interruption of SOF/VEL. 78% of patients had an AE, most of which were mild, and 11% had a serious AE. These efficacy and safety values are comparable to patients enrolled in the same studies who received SOF/VEL for 12 weeks without concomitant use of a PPI (SVR12 97% [2,445 of 2,517 patients]; relapse rate 2% [40 of 2488 patients]). CONCLUSION(S): In Phase 2 and Phase 3 clinical studies, SOF/VEL for 12 weeks was effective and safe in patients with concomitant PPI use. These data support the use of SOF/VEL according to labeled recommendations with respect to co-administration of PPIs and other acid reducing agents.
Volume
2
Issue
2
First Page
76
